tirzepatide is a new investigational medication for the treatment of type 2 diabetes. It is a once-weekly injection that combines three different actions:
Glucagon-like peptide-1 (glp-1) receptor agonist: tirzepatide stimulates the glp-1 receptor, which increases insulin secretion from the pancreas, decreases glucagon secretion, and slows gastric emptying.
Glucagon receptor antagonist: tirzepatide blocks the glucagon receptor, which reduces glucose production by the liver.
Amylin analog: tirzepatide mimics the effects of amylin, a hormone that is deficient in people with diabetes. Amylin helps to regulate blood sugar levels by slowing gastric emptying, reducing appetite, and promoting satiety.
The spectrum of tirzepatide’s action is broad, as it targets multiple pathways involved in glucose regulation. Its triple action may lead to improved glycemic control, weight loss, and potentially even cardiovascular benefits. clinical trials have shown that tirzepatide is associated with significant reductions in a1c, body weight, and systolic blood pressure compared to other glucose-lowering medications.